Glomerulonephritis: immunopathogenesis and immunotherapy
Abstract 'Glomerulonephritis'(GN) is a term used to describe a group of heterogeneous
immune-mediated disorders characterized by inflammation of the filtration units of the kidney …
immune-mediated disorders characterized by inflammation of the filtration units of the kidney …
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
R Lafayette, J Kristensen, A Stone, J Floege, V Tesař… - The Lancet, 2023 - thelancet.com
Background IgA nephropathy is a chronic immune-mediated kidney disease and a major
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Background Sparsentan, a novel, non-immunosuppressive, single-molecule, dual
endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus …
endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus …
[HTML][HTML] Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA …
H Zhang, DV Rizk, V Perkovic, B Maes, N Kashihara… - Kidney international, 2024 - Elsevier
Targeting the alternative complement pathway is an attractive therapeutic strategy given its
role in the pathogenesis of immunoglobulin A nephropathy (IgAN). Iptacopan (LNP023) is …
role in the pathogenesis of immunoglobulin A nephropathy (IgAN). Iptacopan (LNP023) is …
The treatment of primary IgA nephropathy: change, change, change
DJ Caster, RA Lafayette - American Journal of Kidney Diseases, 2024 - Elsevier
IgA nephropathy (IgAN) is the most common glomerular disease in the world. However, the
approach to treatment remains controversial. There has been an explosion of clinical trials …
approach to treatment remains controversial. There has been an explosion of clinical trials …
[HTML][HTML] Targeting the alternative complement pathway with iptacopan to treat IgA nephropathy: design and rationale of the APPLAUSE-IgAN study
DV Rizk, BH Rovin, H Zhang, N Kashihara… - Kidney international …, 2023 - Elsevier
Introduction Targeting the alternative complement pathway (AP) is an attractive therapeutic
strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology …
strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology …
Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy
Y Nihei, H Suzuki, Y Suzuki - Frontiers in Immunology, 2023 - frontiersin.org
Immunoglobulin A (IgA) is the most abundant isotype of antibodies, provides a first line of
defense at mucosal surfaces against pathogens, and thereby contributes to mucosal …
defense at mucosal surfaces against pathogens, and thereby contributes to mucosal …
EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
B Fernández-Fernandez, P Sarafidis… - Clinical Kidney …, 2023 - academic.oup.com
ABSTRACT In the EMPA-KIDNEY (The Study of Heart and Kidney Protection With
Empagliflozin) trial, empagliflozin reduced cardiorenal outcomes by 28%(hazard ratio 0.72; …
Empagliflozin) trial, empagliflozin reduced cardiorenal outcomes by 28%(hazard ratio 0.72; …
[HTML][HTML] IgA nephropathy: the lectin pathway and implications for targeted therapy
J Barratt, RA Lafayette, H Zhang, V Tesar, BH Rovin… - Kidney International, 2023 - Elsevier
Many patients with immunoglobulin A nephropathy (IgAN) progress to kidney failure even
with optimal supportive care. An improved understanding of the pathophysiology of IgAN in …
with optimal supportive care. An improved understanding of the pathophysiology of IgAN in …